CA
ATXS

CoreCap Advisors’s Astria Therapeutics ATXS Stock Holding History

CoreCap Advisors’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,000
Closed -$18.2K – 2648
2024
Q2 		$18.2K Buy
+2,000
New +$19.5K ﹤0.01% 927

Other funds holding ATXS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
VPC
Vestal Point Capital New York $3.58B AUM 189.12% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $3.5B AUM 1,165.83% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

CoreCap Advisors's ATXS Position: Q3 2024 in Review

CoreCap Advisors sold out of Astria Therapeutics (ATXS) in Q3 2024, closing a stake of 2,000 shares — an estimated $18.2K sold.

CoreCap Advisors first reported a position in ATXS in Q2 2024 and held it in 1 quarter. The position peaked at $18.2K in Q2 2024. 103 funds tracked by Wall St. Rank hold ATXS as of Q3 2024.

  • CoreCap Advisors reported no remaining Astria Therapeutics position as of Q3 2024 after selling out during the quarter.
  • CoreCap Advisors sold 2,000 Astria Therapeutics shares in Q3 2024, an estimated $18.2K.
  • CoreCap Advisors first reported a position in Astria Therapeutics in Q2 2024 and held it in 1 quarter.
  • CoreCap Advisors's Astria Therapeutics position peaked at $18.2K in Q2 2024.
  • 103 funds tracked by Wall St. Rank held Astria Therapeutics as of Q3 2024.

Based on CoreCap Advisors's 13F filing for Q3 2024, filed 8 Nov 2024.